Biotec Pharmacon ASA develops new pharmaceutical products for treatment of immune related diseases. The company’s bioactive compound SBG (SBG, soluble beta-1,3/1,6-glucan) has completed clinical phase III studies within two therapeutic indications; treatment of diabetic ulcers and prevention and treatment of oral mucositis. However, these trials did not show positive effect as anticipated. It seems to be caused by an unexpected interaction between SBG and the container material.
The company’s clinical development program also includes immunotherapy of cancer where combination treatment of SBG and monoclonal antibodies currently is in clinical phase I/II. Proof of concept trials with SBG in animals for treatment of Inflamatory Bowel Disease and treatment of Asthma have also started.
